ev3: The Virtues of Focus
Executive Summary
Six years ago, ev3 was launched aiming at a broad attach on cardio- and endovascular disease. But the company found including coronary devices in its mix too difficult and too costly. Instead, the company shifted directions three years ago, with a focus on peripheral and neurovascular disease. In the process, it hopes to address what it calls "the innovation gap," the lack of devices developed specifically for the PVD and neurovascular specialists.
You may also be interested in...
Covidien - Back on Top: An Interview with Richard Meelia
Is there a medical device company today doing better than Covidien? The company is making a huge splash building new businesses and shoring up existing ones. But Covidien, formerly Tyco, hasn't always had it so good. A corporate scandal in the early 2000s brought Tyco's corporate management down and scuttled the healthcare business' strategic plan. After years of sitting on the sidelines, Covidien is back, stronger than ever.
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.